Table 3.
Combined screening tests and rate (%) of PET centers performing each test
| Modalities | Rate (%) | Modalities | Rate (%) |
|---|---|---|---|
| Brain MRI | 39.1 | Cervical cytology | 16.6 |
| Otolaryngologic examination | 0.6 | Pelvic ultrasonography | 19.1 |
| Head and neck CT | 27.1 | Pelvic CT | 32.3 |
| Head and neck MRI | 1.8 | Pelvic MRI | 48.1 |
| Thyroid ultrasonography | 37.4 | Prostate ultrasonography | 26.6 |
| Inspection and palpation of breast | 8.1 | Prostate MRI | 44.2 |
| Breast ultrasonography | 27.9 | Prostate specific antigen (PSA) | 82.2 |
| Mammography | 17.5 | Carcinoembryonic antigen (CEA) | 76.6 |
| Sputum cytology | 10.6 | Cancer antigen 19-9 (CA19-9) | 68.1 |
| Chest X-ray | 11.7 | Cancer antigen 125 (CA125) | 32.6 |
| Chest CT | 57.5 | α-fetoproteins (AFP) | 60.5 |
| Gastric fluoroscopy | 2.6 | Pepsinogen | 41.0 |
| Gastric endoscopy | 14.4 | Squamous cell carcinoma antigen (SCC) | 47.9 |
| Helicobacter pylori infection test | 11.9 | Cytokeratin-19 fragment (CYFRA) | 22.8 |
| Abdominal ultrasonography | 57.4 | Pro-gastrin releasing peptide (Pro-GRP) | 15.8 |
| Abdominal CT | 37.1 | Cancer antigen 15-3 (CA15-3) | 2.5 |
| Abdominal MRI | 15.8 | Neuron specific enolase (NSE) | 4.6 |
| Fecal occult blood test (FOBT) | 71.7 | Thyroglobulin | 11.3 |
| Barium enema | 0.0 | PIVKA-II | 7.5 |
| Colonoscopy | 1.9 | Urinary test | 13.8 |